EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM)ST DENIS, France
Disclosure information not submitted.
6D-01 - Real-World Use and Survival Outcomes of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer and Hormone Receptor-Positive/HER2-Negative Breast Cancer: Insights from the French Early Access Program
Tuesday, August 26, 20251:30 PM - 1:35 PM ET
